RELX's Quality and Safety Lab in Shenzhen Accredited by CNAS

Aug.03.2022
RELX's Quality and Safety Lab in Shenzhen Accredited by CNAS
RELX's Shenzhen quality safety lab gains CNAS certification, ensuring global recognition of its testing reports.

On August 2nd, a Blue Whale Finance journalist learned from RELX Yueke (Fogcore Technology) that its quality and safety laboratory in Shenzhen has received recognition from CNAS (China National Accreditation Board for Laboratories).


According to the information provided, CNAS (China National Accreditation Service For Conformity Assessment) is the English abbreviation for the China National Accreditation Committee for Conformity Assessment. Laboratories accredited by CNAS can issue testing reports that are recognized by more than 100 countries worldwide.


As per reports, the Yooz Quality and Safety Laboratory, mentioned earlier, was established in 2021 and covers an area of 450 square meters, serving as a key support component of the Yooz quality system. The laboratory focuses on testing the physical and electrical properties of products and is the second laboratory accredited by CNAS (China National Accreditation Service) within the company, Fogcore Technology. Yooz's first accredited laboratory, dedicated to testing e-liquid, was certified in August 2020, making it the first e-cigarette brand company to receive CNAS accreditation.


In fact, in daily use, electronic cigarettes in the hands of consumers are inevitably subjected to shocks and impacts, as well as challenges from wind, heat, and cold, with their durability and safety directly affecting the user experience. Therefore, in order to pursue top-quality products, YOOZ, in terms of quality and safety testing, has set up multiple tests including friction, drop, and high temperature in its quality safety laboratory. "At present, we have the ability to carry out testing in accordance with national standards," said Yang Yong, head of the YOOZ Quality Compliance Center. "In addition, we have also improved our testing standards by starting from many invisible details.


For example, YUEKE has an exclusively patented system for assessing suction noise, which helps quality engineers monitor the decibel levels of the sounds emitted during product use in real-time to reduce noise levels to the greatest extent possible and achieve "no disturbance" in terms of hearing. Meanwhile, the company also offers optional testing for cosmetics endurance. Engineers apply skincare products to atomizer rods and observe whether the product's appearance changes in high-temperature, high-humidity environments. This process can test the anti-corrosion abilities of different atomizer rods and identify the most durable products for users.


To address the widely-concerned issue of oil leakage, engineers conducted laboratory experiments simulating high-altitude pressures exceeding 3000 meters above sea level, testing atomized bombs. The tested products greatly mitigate oil leakage caused by changes in pressure.


In March of this year, national standards for electronic cigarettes as well as regulations for their management were issued, marking a move towards the legalization and standardization of the electronic cigarette industry. Yang Yong stated that Yooz will take on its quality responsibilities and strive for the highest quality, creating products that have a pure flavor.


It has been reported that YUEKE, since its inception, has invested a total of 800 million yuan in research and development, creating a matrix of eight large laboratories. In addition to the quality and safety laboratory, there are also innovation laboratories, chemical laboratories, life science laboratories, aerosol laboratories, atomization innovation laboratories, new material laboratories, sensory analysis laboratories, and after-sales testing centers. The quality system covers the entire user experience process.


According to Yang Yong, chemical laboratories can analyze the chemical components of aerosols and sprays, while life science laboratories are responsible for safety testing at the cellular and animal levels. By conducting multiple layers of testing, we ensure that the quality and safety of our products are implemented in every detail.


According to reports, the Yueke Chemical Laboratory tests 19 categories of 140 substances and 12 categories of 102 substances for aerosols. The Life Science Laboratory is capable of conducting six tests, such as cell toxicity, to further confirm product safety.


According to reports, Fogtech has recently been awarded the "License for Tobacco Monopoly Production Enterprise (Electronic Cigarette Product Production Enterprise)". Currently, the company is intensively developing new products that meet national standards, and some products have passed technical evaluations. In its statement, Fogtech said it will continue to aim for a perfect user experience and provide high-quality and reassuring products.


This article contains excerpts or reprints from third-party sources, whose copyright belongs to the original media and author. If there is any infringement, please contact us to delete it. Any organization or individual wishing to reprint must contact the author and refrain from reprinting directly.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia Tobacco Tax Debate Spreads Within Labor as NSW Premier Minns Reaffirms Support for a Cut
Australia’s tobacco excise debate is increasingly exposing differences within the governing Labor Party. New South Wales Labor Premier Chris Minns reaffirmed on September 8 that he supports reducing tobacco excise, arguing that current tax settings are pushing consumers toward cheaper black-market cigarettes. Federal Health Minister Mark Butler continues to oppose an excise cut, while Treasurer Jim Chalmers and Assistant Treasurer Daniel Mulino have recently stopped short of ruling out future changes. The divergence follows the opposition Coalition’s proposal to cut tobacco excise by 80%.
Sep.08
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22